Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MPO | P05164 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.41 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23773705 | 1.00 | CFTR (0.50) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| Ammonia Solution, Strong SCHEMBL2569576 | 0.80 | CFTR (0.56) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL22778846 | 0.79 | CFTR (0.46) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL10236 | 0.78 | — | — | |
| SCHEMBL10446411 | 0.78 | CFTR (0.58) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL30391667 | 0.78 | — | — | |
| SCHEMBL23969984 | 0.78 | CFTR (0.59) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL21424550 | 0.77 | CYP19A1 (0.47) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL22811521 | 0.77 | CYP19A1 (0.47) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| Ammonia Solution, Strong SCHEMBL4915893 | 0.77 | SMN1; SMN2 (0.59) | CFTRSLC6A2SLC6A4SLC6A3GOPC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029739-B2 | SHP2 inhibitor and use thereof | KANAPH THERAPEUTICS INC. (KR) | 2024-07-09 | — | — | US | disclosed |
| US-20220119383-A1 | QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS | GILEAD SCIENCES, INC. | 2022-04-21 | — | — | US | disclosed |
| US-11124496-B2 | Imidazolidine compounds | ELI LILLY AND COMPANY (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210253565-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-08-19 | — | — | US | disclosed |
| US-20210061785-A1 | IMIDAZOLIDINE COMPOUNDS | ELI LILLY AND COMPANY | 2021-03-04 | — | — | US | disclosed |
| US-20210038606-A1 | Modulators of Rho-associated Protein Kinase | REDX PHARMA LIMITED (GB) | 2021-02-11 | — | — | US | disclosed |
| US-20200087270-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2020-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253565-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, LIPC | CFTR 3365/4885SLC6A2 2903/4885SLC6A4 2460/4885 |
| US-20200087270-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | CFTR 43/4885SLC6A2 1936/4885SLC6A4 2344/4885 |
| US-20210061785-A1 | IMIDAZOLIDINE COMPOUNDS | SLC10A1, SLC10A2, CPT1A | CFTR 184/4885SLC6A2 1375/4885SLC6A4 1826/4885 |
| US-20210038606-A1 | Modulators of Rho-associated Protein Kinase | ROCK2, ROCK1, RHOA | CFTR 1900/4885SLC6A2 4242/4885SLC6A4 4660/4885 |
| US-20220119383-A1 | QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS | ITGB7, ITGB1, ITGA2B | CFTR 152/4885SLC6A2 1459/4885SLC6A4 1835/4885 |
| US-12029739-B2 | SHP2 inhibitor and use thereof | PTPN1, PTPN5, PTPN2 | CFTR 313/4885SLC6A2 4742/4885SLC6A4 4745/4885 |
| US-11124496-B2 | Imidazolidine compounds | SLC10A1, SLC10A2, CPT1A | CFTR 184/4885SLC6A2 1375/4885SLC6A4 1826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.